EUVIMEDEUVIMED entdecken
Crossref

CCR4 predicts the efficacy of abatacept in rheumatoid arthritis patients through the estimation of Th17 and Treg cell abundance

Shigeru Tanaka iD, Keishi Etori, Koto Hattori, Jun Tamura, Kei Ikeda, Takahiro Kageyama, Kazuyuki Meguro, Taro Iwamoto, Arifumi Iwata, Shunsuke Furuta, Akira Suto, Kotaro Suzuki und 1 weitere

Modern Rheumatology · 2024

DOI: 10.1093/mr/road077 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Shigeru Tanaka und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan. Hauptthemen laut MEDLINE: Abatacept, Arthritis, Rheumatoid, Receptors, CCR4, Th17 Cells. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Predicting the efficacy of biological disease–modifying antirheumatic drugs is challenging. In this study, we aimed to explore markers that predict the efficacy of abatacept in rheumatoid arthritis (RA) patients.

Methods

Thirty RA patients receiving abatacept were recruited, and peripheral blood mononuclear cells from the participants were subjected to DNA microarray analysis. The expression of CC chemokine receptor 4 (CCR4), which was selected by the result of DNA microarray, was determined by flow cytometry in 16 newly diagnosed treatment-naïve RA patients. CCR4 expression on each helper T-cell subset was also measured.

Results

CCR4 was upregulated in the abatacept responder. The expression levels of CCR4 were significantly correlated with the improvement of the Clinical Disease Activity Index. CCR4 expression was predominantly observed in CD4+ T cells in peripheral blood mononuclear cells. The percentage of CCR4-expressing CD4+ T cells was significantly higher in RA patients than in healthy individuals. Interestingly, Th17 and Treg cells expressed high levels of CCR4 compared to non-Th17-related helper T cells.

Conclusions

CCR4 is a Th17- and Treg-related gene, and the high CCR4 expression in peripheral blood samples may predict the efficacy of abatacept in RA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AbataceptArthritis, RheumatoidReceptors, CCR4Th17 CellsT-Lymphocytes, RegulatoryAntirheumatic AgentsHumansMaleFemaleMiddle AgedAdultTreatment OutcomeAged

Stichwörter der Autor:innen

CCR4Rheumatoid arthritisTh17Tregabatacept

Substanzen

AbataceptReceptors, CCR4Antirheumatic AgentsCCR4 protein, human

Autor:innen und Institutionen

  • Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Graduate School of Medicine, Institute for Advanced Academic Research, Chiba, Japan.
  • Chiba University, Synergy Institute for Futuristic Mucosal Vaccine Research and Development (cSIMVa), Chiba, Japan.

ORCID-Profile: Shigeru Tanaka

Zitieren

APA

Tanaka, S., Etori, K., Hattori, K., Tamura, J., Ikeda, K., Kageyama, T., Meguro, K., Iwamoto, T., Iwata, A., Furuta, S., Suto, A., Suzuki, K., & Nakajima, H. (2024). CCR4 predicts the efficacy of abatacept in rheumatoid arthritis patients through the estimation of Th17 and Treg cell abundance. Modern Rheumatology. https://doi.org/10.1093/mr/road077

Vancouver

Tanaka S, Etori K, Hattori K, Tamura J, Ikeda K, Kageyama T, et al. CCR4 predicts the efficacy of abatacept in rheumatoid arthritis patients through the estimation of Th17 and Treg cell abundance. Modern Rheumatology. 2024. doi:10.1093/mr/road077

BibTeX
@article{Tanaka2024,
  author = {Tanaka, Shigeru and Etori, Keishi and Hattori, Koto and Tamura, Jun and Ikeda, Kei and Kageyama, Takahiro and Meguro, Kazuyuki and Iwamoto, Taro and Iwata, Arifumi and Furuta, Shunsuke and Suto, Akira and Suzuki, Kotaro and Nakajima, Hiroshi},
  title = {CCR4 predicts the efficacy of abatacept in rheumatoid arthritis patients through the estimation of Th17 and Treg cell abundance},
  journal = {Modern Rheumatology},
  year = {2024},
  doi = {10.1093/mr/road077}
}
Kostenlos starten →